Six years in, long Covid is still with many Vermonters — and they say the system is failing them

Long Covid patients in Vermont report debilitating, multi-system symptoms with no clear diagnostics or proven therapies, leaving many unable to work and reliant on a strained healthcare system; a 2023 state report found about 11% of adults who tested positive experienced symptoms lasting three months or longer. Rising costs and benefit uncertainty — marketplace premiums have more than doubled, patients cite drug costs up to $80,000/year, and insurers are denying or refusing reauthorization for treatments — coincide with policy setbacks, including a stalled $1 billion NIH proposal and the HHS elimination of a long Covid research office. The combination of patient demand for coordinated multi-specialty care, regulatory uncertainty and constrained access points to sector-specific opportunities and risks in specialty care, therapeutics and insurers, but limited immediate broad-market impact.

Analysis

Market structure: Persistent long Covid creates durable demand for diagnostics, multispecialty outpatient clinics, telehealth and home-health services as patients require repeat testing, care coordination and pacing strategies. Winners: large diagnostics (DGX, LH), telehealth (TDOC), integrated care/managed care platforms (UNH/Optum) and home-health providers (AMED, OPCH) that can scale interdisciplinary care; losers: small regional hospitals and payers with limited specialty networks who face rising chronic claims and denials. Expect pricing power for specialized infusion and novel outpatient therapies if payers approve them, while broad elective-revenue streams remain pressured by higher premiums.

Risk assessment: Major tail risks include abrupt federal funding cuts or regulatory moves reducing research (already signaled by HHS restructuring) and large-scale payer coverage denials leading to litigation or write-downs for providers; probability moderate, impact high over 12–36 months. Short-term (0–3 months) operational risk: staffing shortages and prior-authorization denials that can delay revenue; medium-term (3–12 months): state/federal policy shifts and insurer rate-setting; long-term (>12 months): emergence of validated diagnostics/therapies could re-rate winners. Hidden dependency: patient ability to pay and subsidy availability is a lever — if marketplace subsidies shrink by >20–30%, utilization of pricey outpatient therapies could fall substantially.

trade implications: Tactical longs: 1–3% positions in DGX or LH (diagnostics) and 1–2% in TDOC (telehealth) on 3–9 month horizons to capture volume tailwinds; buy 3–6 month call spreads to cap capital. Core/strategic: 1–2% long in UNH (Optum) via 9–18 month LEAP calls to play integrated care capture and pricing leverage. Pairs: long AMED (home health) vs short a small regional hospital operator (e.g., CYH) to play shift to outpatient; time horizon 6–12 months. Use options to express conviction: buy TDOC 6-month call spread and sell short-dated hospital operator calls to finance.

contrarian angles: The market underprices recurring revenue from chronic post-viral care — consensus treats long Covid as transitory but prevalence surveys (Vermont 11% among positives) imply a multi-year care tail supporting diagnostics and home health revenue growth of +5–15% for winners over 2–3 years. Reaction to policy hostility may be overdone for large vertically integrated players (UNH, DGX) who can negotiate reimbursement; downside is concentrated on smaller providers and insurers. Historical parallel: post-SARS chronic sequelae produced durable specialty markets; if a validated biomarker or reimbursed therapeutic emerges within 12–24 months, re-rating of focused biotech/diagnostics could be sharp (30%+ for small caps).

Key Decisions for Investors

• Establish a 1–3% tactical long position in Quest Diagnostics (DGX) or LabCorp (LH) over 3–9 months; use 3–6 month call spreads to limit capital outlay and target a 20–35% upside if outpatient testing volumes rise 5–10%.
• Add a 1–2% strategic long in UnitedHealth Group (UNH) via 9–18 month LEAP calls to capture Optum’s pricing and care-management advantage; exit or trim if CMS/Medicaid reimbursements move unfavorably by >5% within 6 months.
• Take a 1% long in Teladoc Health (TDOC) using 3–6 month call spreads (buy calls financed with OTM calls) to play telehealth demand; cover if monthly active user growth stalls below +2% MoM for two consecutive months.
• Implement a pair trade: long 1% Amedisys (AMED) vs short 1% Community Health Systems (CYH) over 6–12 months to play shift to home health; unwind if AMED outpatient revenue growth <3% YoY or CYH EBITDA margin expands >200 bps.
• Monitor HHS policy, CMS national coverage decisions and Congressional appropriations on long Covid research over the next 30–90 days; if funding is restored or a national coverage memo for outpatient therapies is issued, add to biotech/diagnostic exposure (increase positions by 50%).